Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2

AIDS Res Hum Retroviruses. 1999 Jun 10;15(9):803-10. doi: 10.1089/088922299310700.

Abstract

The role of Bcl-2, Bax, and Bcl-x in the apoptosis of T lymphocytes in HIV-infected individuals was investigated. A strong correlation between Bcl-2 downregulation and spontaneous apoptosis has been reported by various groups in short-term cultures of CD8+ but not of CD4+ T lymphocytes. We describe a similar correlation in CD4+ T cells and provide an explanation why Bcl-2 downregulation in these cells has not been detected so far. In apoptotic cells not only Bcl-2, but also the CD4 surface receptors, are downregulated, preventing the detection of these cells in flow cytometric analysis. In contrast to Bcl-2, no correlation is detectable between Bax or Bcl-x expression and apoptosis. T lymphocytes of HIV-infected, but not of control, individuals display ex vivo a heterogeneous Bcl-2 expression pattern with a low and a high Bcl-2-expressing lymphocyte fraction. The proportion of low Bcl-2-expressing T cells correlates with a higher viral load in these individuals. Antiretroviral therapy significantly reduces the proportion of low Bcl-2-expressing lymphocytes, which is associated with a decrease in apoptosis. Bcl-2 downregulation and spontaneous apoptosis of T lymphocytes from HIV-infected individuals can be partially prevented by the exogeneous addition of IL-2, but not of IL-12, IL-4, or antibodies that prevent the CD95/CD95 ligand pathway of apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Antibodies, Monoclonal / metabolism
  • Apoptosis*
  • CD4 Antigens / metabolism
  • CD4-Positive T-Lymphocytes / cytology*
  • CD4-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / cytology*
  • CD8-Positive T-Lymphocytes / metabolism
  • Down-Regulation*
  • Flow Cytometry
  • HIV Infections / blood*
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Interleukin-12 / metabolism
  • Interleukin-2 / metabolism*
  • Interleukin-2 / pharmacology
  • Interleukin-4 / metabolism
  • Proto-Oncogene Proteins / biosynthesis*
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Signal Transduction
  • bcl-2-Associated X Protein
  • bcl-X Protein
  • fas Receptor / metabolism

Substances

  • Anti-HIV Agents
  • Antibodies, Monoclonal
  • BAX protein, human
  • BCL2L1 protein, human
  • CD4 Antigens
  • HIV Protease Inhibitors
  • Interleukin-2
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Reverse Transcriptase Inhibitors
  • bcl-2-Associated X Protein
  • bcl-X Protein
  • fas Receptor
  • Interleukin-12
  • Interleukin-4